Synaptotagmin-like protein 5 (SYTL5)

Synaptotagmin-like protein 5 (SYTL5) is a member of the SYTL (Slp) protein family containing both an N-terminal Slp homology domain (SHD) and two C-terminal C2 lipid-binding domains[1][2]. SYTL5 functions as a Rab27A effector protein, interacting with the active GTP-bound form of Rab27A and participating in the regulation of vesicle trafficking, as well as plasma membrane and mitochondrial localization[1][2]. Its primary biological functions include roles in membrane trafficking, exocytosis, and regulation of mitochondrial dynamics; it also acts as a negative regulator of the Warburg effect and tumorigenesis in cancer models, with reduced expression linked to poor prognosis in some cancers such as adrenocortical carcinoma[1]. The protein is predominantly expressed in a tissue-specific manner, with high expression in the adrenal gland, placenta, and liver[2]. There are no drugs or direct targeting agents currently identified for SYTL5, and it is not an established therapeutic or diagnostic target at this time.

Other names

Synaptotagmin-like protein 5SYTL5SLP5Slp5exophilin 9Exophilin-9